{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:46:19Z","timestamp":1793936779531,"version":"4.8.0"},"reference-count":30,"publisher":"The Pediatric Pharmacy Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVES<\/jats:title>\n                  <jats:p>Literature is limited regarding ideal micafungin dosing in pediatric patients with hematologic malignancies receiving chemotherapy or hematopoietic stem cell transplantation. Micafungin is an intravenous echinocandin with activity against Candida and Aspergillus species and has a favorable safety profile compared with other antifungal classes. Our objective was to evaluate the breakthrough invasive fungal infection (IFI) rate in pediatric patients who received a prophylactic micafungin course at our institution.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>A single-center, retrospective study was conducted between January 1, 2011, and July 31, 2017, to determine the IFI rate in patients receiving micafungin prophylaxis. Patients with suspected IFI were evaluated for probable or proven infection based on European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group Consensus Group invasive fungal disease definitions. Statistical analyses were descriptive.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>A total of 170 prophylactic micafungin courses from 129 unique patients ages &amp;lt;12 years at a median dose of 3 mg\/kg daily were identified. The rate of probable or proven breakthrough IFIs was 2.4% as determined by clinical, radiologic, microbiologic, and histopathologic criteria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>A low rate of breakthrough IFI was seen with micafungin prophylaxis that is consistent with prior published adult hematopoietic stem cell transplantation studies. Micafungin was well tolerated, with liver function test elevations being transient in most cases and thought to be related to alternative factors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.5863\/1551-6776-29.4.379","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T21:21:38Z","timestamp":1723584098000},"page":"379-384","source":"Crossref","is-referenced-by-count":3,"title":["A Retrospective Analysis of Micafungin Prophylaxis in Children Under 12 Years Undergoing Chemotherapy or Hematopoietic Stem Cell Transplantation"],"prefix":"10.5863","volume":"29","author":[{"given":"Breana K.","family":"Goscicki","sequence":"first","affiliation":[{"name":"Department of Pharmacy (BKG), UPMC Children\u2019s Hospital of Pittsburgh, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley Q.","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (SQY, NC), Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Mathew","sequence":"additional","affiliation":[{"name":"Hematology (SM), Pfizer, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Mauguen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics (AM), Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (SQY, NC), Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"2024081321211483800_i2331-348X-29-4-379-b01","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/j.1439-0507.1999.00496.x","article-title":"Five-year survey of invasive aspergillosis in a pediatric cancer centre: epidemiology, management and longterm survival","volume":"42","author":"Groll","year":"1999","journal-title":"Mycoses"},{"key":"2024081321211483800_i2331-348X-29-4-379-b02","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/pbc.22750","article-title":"Incidence of bacteremias and invasive mycoses in children with acute non-lymphoblastic leukemia: results from a multi-center Italian study","volume":"55","author":"Castagnola","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"2024081321211483800_i2331-348X-29-4-379-b03","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2141.2009.08072.x","article-title":"Epidemiology of paediatric invasive fungal infections: a case-control study of risk factors in acute leukaemia or post stem cell transplant","volume":"149","author":"Hale","year":"2010","journal-title":"Br J Haematol"},{"key":"2024081321211483800_i2331-348X-29-4-379-b04","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/pbc.23005","article-title":"Invasive fungal infections in pediatric oncology","volume":"56","author":"Mor","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"2024081321211483800_i2331-348X-29-4-379-b05","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/ejh.12910","article-title":"Retrospective study on the incidence and outcome of proven and probable invasive fungal infections in high-risk pediatric onco-hematological patients","volume":"99","author":"Cesaro","year":"2017","journal-title":"Eur J Haematol"},{"issue":"1","key":"2024081321211483800_i2331-348X-29-4-379-b06","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/pbc.23415","article-title":"Antifungal prophylaxis in pediatric hematology\/oncology: new choices & new data","volume":"59","author":"Dvorak","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2024081321211483800_i2331-348X-29-4-379-b07","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/01.mph.0000155861.38641.ca","article-title":"Invasive fungal infections in pediatric oncology patients: 11 year experience at a single institution","volume":"27","author":"Rosen","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"issue":"27","key":"2024081321211483800_i2331-348X-29-4-379-b08","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.20.00158","article-title":"Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients","volume":"38","author":"Lehrnbecher","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024081321211483800_i2331-348X-29-4-379-b09","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/pbc.22449","article-title":"Micafungin: a brief review of pharmacology, safety, and antifungal efficacy in pediatric patients","volume":"55","author":"Lehrnbecher","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2024081321211483800_i2331-348X-29-4-379-b10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jpids\/pix030","article-title":"Risk factors for invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: a systematic review","volume":"7","author":"Fisher","year":"2018","journal-title":"J Pediatr Inf Dis Soc"},{"key":"2024081321211483800_i2331-348X-29-4-379-b11","author":"Mycamine (micafungin) [prescribing information]","year":"2020"},{"key":"2024081321211483800_i2331-348X-29-4-379-b12","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/INF.0b013e31817275e6","article-title":"Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial","volume":"27","author":"Queiroz-Telles","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"2024081321211483800_i2331-348X-29-4-379-b13","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1128\/AAC.01679-09","article-title":"Population pharmacokinetics of micafungin in neonates and young infants","volume":"54","author":"Hope","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2024081321211483800_i2331-348X-29-4-379-b14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/clpt.2009.200","article-title":"Safety and pharmacokinetics of repeat-dose micafungin in young infants","volume":"87","author":"Benjamin","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"2024081321211483800_i2331-348X-29-4-379-b15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/INF.0b013e3181910e2d","article-title":"Pharmacokinetics of an elevated dosage of micafungin in premature neonates","volume":"28","author":"Smith","year":"2009","journal-title":"Pediatric Infect Dis J"},{"issue":"8","key":"2024081321211483800_i2331-348X-29-4-379-b16","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1128\/AAC.49.8.3317-3324.2005","article-title":"Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients","volume":"49","author":"Seibel","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"2024081321211483800_i2331-348X-29-4-379-b17","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1128\/AAC.00398-07","article-title":"Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing","volume":"51","author":"Hope","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2024081321211483800_i2331-348X-29-4-379-b18","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/MPH.0000000000000218","article-title":"Pharmacokinetic and safety profiles of repeated-dose prophylactic micafungin in children and adolescents undergoing hematopoietic stem cell transplantation","volume":"37","author":"Albano","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"2024081321211483800_i2331-348X-29-4-379-b19","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1097\/INF.0b013e3182127eaf","article-title":"Safety of micafungin in pediatric clinical trials","volume":"30","author":"Arrieta","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"2024081321211483800_i2331-348X-29-4-379-b20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/INF.0000000000002032","article-title":"Efficacy and safety of echinocandins for the treatment of invasive candidiasis in children: a meta-analysis","volume":"38","author":"Tsekour","year":"2019","journal-title":"Pediatr Infect Dis"},{"key":"2024081321211483800_i2331-348X-29-4-379-b21","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"Van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"S6","key":"2024081321211483800_i2331-348X-29-4-379-b22","doi-asserted-by":"crossref","first-page":"s652","DOI":"10.1093\/cid\/civ818","article-title":"Safety and efficacy of intermittent intravenous administration of high-dose micafungin","volume":"61","author":"Neofytos","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2024081321211483800_i2331-348X-29-4-379-b23","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3390\/children9030372","article-title":"Prospective study on prophylactic micafungin sodium against invasive fungal disease during neutropenia in pediatric & adolescent patients undergoing autologous hematopoietic stem cell transplantation","volume":"9","author":"Kim","year":"2022","journal-title":"Children"},{"key":"2024081321211483800_i2331-348X-29-4-379-b24","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/bmt.2014.136","article-title":"Efficacy and safety of micafungin for the prophylaxis of invasive fungal infection during neutropenia in children and adolescents undergoing allogeneic hematopoietic SCT","volume":"49","author":"Park","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"2024081321211483800_i2331-348X-29-4-379-b25","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2024081321211483800_i2331-348X-29-4-379-b26","unstructured":"National Cancer Institute\n          . Common terminology criteria for adverse events v.5.0. 2017. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed \u00adDecember 2017."},{"key":"2024081321211483800_i2331-348X-29-4-379-b27","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/cid\/civ293","article-title":"Epidemiology and outcome of fungemia in a cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031)","volume":"61","author":"Cornely","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2024081321211483800_i2331-348X-29-4-379-b28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.idc.2015.10.012","article-title":"Antifungal agents: spectrum of activity, pharmacology, and clinical indications","volume":"30","author":"Nett","year":"2016","journal-title":"Infect Dis Clin North Am"},{"issue":"4","key":"2024081321211483800_i2331-348X-29-4-379-b29","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11046-012-9552-9","article-title":"Rhodotorula fungemia of an intensive care unit patient and review of published cases","volume":"174","author":"Spiliopoulou","year":"2012","journal-title":"Mycopathologica"},{"key":"2024081321211483800_i2331-348X-29-4-379-b30","first-page":"1","article-title":"Assessment of micafungin dosage regimens against Candida spp. in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic\/pharmacodynamic analysis using Monte Carlo simulation","volume":"15","author":"Wei","year":"2023","journal-title":"J Chemother"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/4\/379\/3419124\/i2331-348x-29-4-379.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/29\/4\/379\/3419124\/i2331-348x-29-4-379.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:41:53Z","timestamp":1738780913000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/29\/4\/article-p379.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,8,13]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-29.4.379","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}